Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies

被引：33

作者：

Pulanco, Marc C. ^{[1
]}

Madsen, Anne T. ^{[1
,2
]}

Tanwar, Ankit ^{[1
,3
]}

Corrigan, Devin T. ^{[1
]}

Zang, Xingxing ^{[1
,2
,3
,4
]}

机构：

[1] Albert Einstein Coll Med, Dept Microbiol & Immunol, New York, NY 10461 USA

[2] Albert Einstein Coll Med, Dept Urol, New York, NY 10461 USA

[3] Albert Einstein Coll Med, Dept Oncol, New York, NY 10461 USA

[4] Albert Einstein Coll Med, Dept Med, New York, NY 10461 USA

来源：

CELLULAR & MOLECULAR IMMUNOLOGY | 2023年 / 20卷 / 07期

关键词：

B7; family; immune checkpoints; metabolic regulators; glycobiology; therapy resistance; T-CELL SURVIVAL; ANTIBODY TARGETING PD-1; BREAST-CANCER CELLS; BISPECIFIC ANTIBODY; ACQUIRED-RESISTANCE; LUNG-CANCER; B7; FAMILY; PROGRAMMED DEATH-1; ANTI-PD-1; THERAPY; MONOCLONAL-ANTIBODY;

D O I：

10.1038/s41423-023-01019-8

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The B7/CD28 families of immune checkpoints play vital roles in negatively or positively regulating immune cells in homeostasis and various diseases. Recent basic and clinical studies have revealed novel biology of the B7/CD28 families and new therapeutics for cancer therapy. In this review, we discuss the newly discovered KIR3DL3/TMIGD2/HHLA2 pathways, PD-1/PD-L1 and B7-H3 as metabolic regulators, the glycobiology of PD-1/PD-L1, B7x (B7-H4) and B7-H3, and the recently characterized PD-L1/B7-1 cis-interaction. We also cover the tumor-intrinsic and -extrinsic resistance mechanisms to current anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapies in clinical settings. Finally, we review new immunotherapies targeting B7-H3, B7x, PD-1/PD-L1, and CTLA-4 in current clinical trials.

引用

页码：694 / 713

页数：20

共 50 条

[41] Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway
Ossevoort, MA
Ringers, J
Kuhn, EM
Boon, L
Lorré, K
van den Hout, Y
Bruijn, JA
de Boer, H
Jonker, M
de Waele, P
TRANSPLANTATION, 1999, 68 (07) : 1010 - 1018
[42] Upregulation of the B7/CD28 family member B7-H3 in bladder cancer
Wu, Deyao
Zhang, Zichun
Pan, Huixing
Fan, Yuanfeng
Qu, Ping
Zhou, Jian
ONCOLOGY LETTERS, 2015, 9 (03) : 1420 - 1424
[43] Allograft Rejection with αCD28 and αB7 Costimulation Blockade Is Not Correlated with CD28-Graft Infiltrating T Lymphocytes
O'Neill, Natalie A.
Zhang, Tianshu
Sun, Wenji
Braileanu, Gheorghe
Tatarov, Ivan
Hassanein, Wessam
Sendil, Selin
Parsell, Dawn M.
Pierson, Richard N., III
Azimzadeh, Agnes M.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2016, 223 (04) : S146 - S146
[44] Blockade of B7/CD28 pathway results in the generation of alternatively activated macrophages.
Tzachanis, D
Nadler, LM
Boussiotis, VA
BLOOD, 2000, 96 (11) : 374A - 374A
[45] CD28:B7 interaction is necessary for the protective effect of T cell vaccination in EAE
Yang, Yuhong
Ratts, Robert B.
Hussain, Rehana Z.
Northrop, Sara C.
Ben, Li-Hong
Lovett-Racke, Amy
Racke, Michael K.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (07) : 2032 - 2042
[46] T细胞活化的辅助刺激因子:CD28和B7
王孟昭
崔莲仙
国外医学(分子生物学分册), 1998, (02) : 71 - 75
[47] Role of CD28/B7 costimulation in the dexamethasone-induced suppression of IFN-γ
Agarwal, SK
Marshall, GD
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2000, 20 (11): : 927 - 934
[48] THE CD28/CTLA-4/B7 RECEPTOR SYSTEM IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
LINSLEY, PS
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (06): : 2429 - 2430
[49] Expression of B7 and CD28 family genes in newly diagnosed type 1 diabetes
Pruul, Katrin
Kisand, Kalle
Alnek, Kristi
Metskuela, Kaja
Heilman, Kaire
Peet, Aleksandr
Varik, Karin
Uibo, Raivo
HUMAN IMMUNOLOGY, 2013, 74 (10) : 1251 - 1257
[50] Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
Salomon, B
Bluestone, JA
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 : 225 - 252

← 1 2 3 4 5 →